Literature DB >> 8866652

Polyethylene glycol modification: relevance of improved methodology to tumour targeting.

G E Francis1, C Delgado, D Fisher, F Malik, A K Agrawal.   

Abstract

Of all the polymers applied to molecule altering structural chemistry, polyethylene glycol (PEG) modification has numerous benefits and relatively few drawbacks. PEG is now increasingly being applied to the problems of tumour targeting, both in the context of the passive targeting of PEG-liposomes and in active targeting strategies using PEGylated anti-tumour antibodies. PEG can also serve as a useful linker molecule between targeting moieties and other agents, including cytotoxic or imaging agents and targeted liposomes. Despite these demonstrated benefits and the level of attention which PEGylation has received, relatively little consideration has been given to two key areas: first, the extent to which the coupling method has an impact on both the functionality of the PEG-adduct and the acquisition of beneficial properties; second, that the impact of PEGylation on biodistribution is complex, thus any attempt to optimise a PEG-peptide or PEG-liposome for a particular task must involve an examination of all the individual facets of the effects of PEGylation. Studies investigating the underlying principles of tumour targeting suggest that current views concerning the optimisation of PEGylated vehicles for tumour localisation need to be re-examined.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8866652     DOI: 10.3109/10611869608996824

Source DB:  PubMed          Journal:  J Drug Target        ISSN: 1026-7158            Impact factor:   5.121


  10 in total

1.  Site specific discrete PEGylation of (124)I-labeled mCC49 Fab' fragments improves tumor MicroPET/CT imaging in mice.

Authors:  Haiming Ding; Michelle M Carlton; Stephen P Povoski; Keisha Milum; Krishan Kumar; Shankaran Kothandaraman; George H Hinkle; David Colcher; Rich Brody; Paul D Davis; Alex Pokora; Mitchell Phelps; Edward W Martin; Michael F Tweedle
Journal:  Bioconjug Chem       Date:  2013-10-31       Impact factor: 4.774

Review 2.  Nanogels as pharmaceutical carriers: finite networks of infinite capabilities.

Authors:  Alexander V Kabanov; Serguei V Vinogradov
Journal:  Angew Chem Int Ed Engl       Date:  2009       Impact factor: 15.336

3.  EGFR-targeted stearoyl gemcitabine nanoparticles show enhanced anti-tumor activity.

Authors:  Michael A Sandoval; Brian R Sloat; Dharmika S P Lansakara-P; Amit Kumar; B Leticia Rodriguez; Kaoru Kiguchi; John Digiovanni; Zhengrong Cui
Journal:  J Control Release       Date:  2011-08-17       Impact factor: 9.776

Review 4.  Pegylation: a novel process for modifying pharmacokinetics.

Authors:  J M Harris; N E Martin; M Modi
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

5.  Design, synthesis, and characterization of pH-sensitive PEG-PE conjugates for stimuli-sensitive pharmaceutical nanocarriers: the effect of substitutes at the hydrazone linkage on the ph stability of PEG-PE conjugates.

Authors:  Amit A Kale; Vladimir P Torchilin
Journal:  Bioconjug Chem       Date:  2007-02-20       Impact factor: 4.774

Review 6.  Factors affecting the clearance and biodistribution of polymeric nanoparticles.

Authors:  Frank Alexis; Eric Pridgen; Linda K Molnar; Omid C Farokhzad
Journal:  Mol Pharm       Date:  2008-08-04       Impact factor: 4.939

7.  Environment-Responsive Polymers for Coating of Pharmaceutical Nanocarriers(,).

Authors:  A A Kale; V P Torchilin
Journal:  Polym Sci Ser A Chem Phys       Date:  2009-06

8.  Multifunctional Targeting Liposomes of Epirubicin Plus Resveratrol Improved Therapeutic Effect on Brain Gliomas.

Authors:  Dehua Kong; Wenyu Hong; Miao Yu; Yanxia Li; YaXin Zheng; Xue Ying
Journal:  Int J Nanomedicine       Date:  2022-03-14

Review 9.  Protein PEGylation: Navigating Recombinant Protein Stability, Aggregation, and Bioactivity.

Authors:  Lindiwe Khumbuzile Zuma; Nothando Lovedale Gasa; Xolani Henry Makhoba; Ofentse Jacob Pooe
Journal:  Biomed Res Int       Date:  2022-07-25       Impact factor: 3.246

10.  Targeted Therapy for Acute Autoimmune Myocarditis with Nano-Sized Liposomal FK506 in Rats.

Authors:  Keiji Okuda; Hai Ying Fu; Takashi Matsuzaki; Ryo Araki; Shota Tsuchida; Punniyakoti V Thanikachalam; Tatsuya Fukuta; Tomohiro Asai; Masaki Yamato; Shoji Sanada; Hiroshi Asanuma; Yoshihiro Asano; Masanori Asakura; Haruo Hanawa; Hiroyuki Hao; Naoto Oku; Seiji Takashima; Masafumi Kitakaze; Yasushi Sakata; Tetsuo Minamino
Journal:  PLoS One       Date:  2016-08-08       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.